Transfusion-associated circulatory overload

Geron Presentations at Upcoming EHA Annual Meeting to Report Updated Durability, Disease Modification and Favorable Patient Reported Outcomes (PRO) in Imetelstat-Treated Lower Risk MDS Patients in IMerge Phase 3

Retrieved on: 
Thursday, May 11, 2023

The continuous TI for more than one year represents substantial relief from transfusion-associated complications for this lower risk MDS patient population.

Key Points: 
  • The continuous TI for more than one year represents substantial relief from transfusion-associated complications for this lower risk MDS patient population.
  • As reported in January, 39.8% (47/118) of imetelstat-treated patients versus 15.0% (9/60) of placebo-treated patients achieved the study primary endpoint of 8-week TI (P
  • As noted in the abstract, a main therapeutic goal in lower risk MDS is to alter disease biology by eradicating malignant clones.
  • Of the 178 patients enrolled in IMerge Phase 3, 22.0% of imetelstat-treated patients and 21.7% of placebo-treated patients had baseline cytogenetic abnormalities.